Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Peak Pharmaceutical Partners with Shanghai Pharma Subsidiary to Optimize Neffy Supply Chain and Channel Development in China

Fineline Cube May 26, 2026
Company Deals

Insilico Medicine and Eterna Therapeutics Expand AI-Driven Partnership into Skin Anti-Aging and Scientific Skincare

Fineline Cube May 26, 2026
Company Deals

ZBD Pharmaceutical Secures Marketing Rights for Teruisi’s CD20-Targeted ADC TRS005 in Relapsed/Refractory Non-Hodgkin Lymphoma

Fineline Cube May 26, 2026
Company Deals

Sinocelltech Files for Hong Kong Secondary Listing to Expand Global Capital Access and Therapeutic Portfolio

Fineline Cube May 25, 2026
Company Deals Medical Device

Lifetech Scientific to Acquire Starway Medical Technology in $276 Million Deal to Expand Structural Heart Portfolio

Fineline Cube May 25, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Changchun High & New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease

Fineline Cube May 26, 2026
Company Drug

China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn’s Disease

Fineline Cube May 26, 2026
Policy / Regulatory

NHSA Orders Investigation into Unreasonable Medical Insurance Restrictions

Fineline Cube Dec 23, 2022

The National Healthcare Security Administration (NHSA) has released a notification to medical insurance departments across...

Company Drug

Fosun Pharma’s Avatrombopag Receives NMPA Review for Chronic ITP Indication

Fineline Cube Dec 23, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that another...

Company Deals

Nanjing Pharmaceutical to Acquire Majority Stakes in Three Jiangsu Subsidiaries

Fineline Cube Dec 23, 2022

China-based Shanghai-listed Nanjing Pharmaceutical Co., Ltd (SHA: 600713) is set to acquire a respective 55%,...

Company Deals

MSD and Kelun Biotech Ink Record-Breaking ADC Deal

Fineline Cube Dec 23, 2022

Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest...

Policy / Regulatory

NMPA and GAC Release Notification on Import and Export Management of Narcotic Drugs

Fineline Cube Dec 23, 2022

The National Medical Products Administration (NMPA) and the General Administration of Customs (GAC) have released...

Company Drug

Shyndec’s Generic Cytosar-U Gains Marketing Approval in China

Fineline Cube Dec 23, 2022

China-based Shanghai Shyndec Pharmaceutical Co., Ltd (SHA: 600420) has announced that its generic version of...

Company Medical Device

Sino Medical Sciences’ NC Rockstar Catheter Approved by US FDA

Fineline Cube Dec 23, 2022

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving market approval from the...

Company Drug

Antengene Files for Xpovio Approval in Macau, Malaysia, and Thailand

Fineline Cube Dec 23, 2022

Antengene Corp., Ltd (HKG: 6996) has announced market filings for its Xpovio (selinexor) in Macau,...

Drug

Eisai and Biogen Initiate BLA in China for Alzheimer’s Therapy Lecanemab

Fineline Cube Dec 23, 2022

Japan-based Eisai Co., Ltd (TYO: 4523) and its US co-development partner Biogen Inc. (NASDAQ: BIIB)...

Company Deals

Qitan Tech Raises RMB 700 Million in Series C Financing Led by Meituan

Fineline Cube Dec 23, 2022

Qitan Tech, a nanopore gene sequencer maker based in Chengdu, has reportedly raised RMB 700...

Company Drug

Kanghong’s Escitalopram Oral Solution Receives NMPA Marketing Approval

Fineline Cube Dec 23, 2022

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving marketing approval from...

Company Drug

Tonghua Dongbao Receives NMPA Approval for THDBH151 Clinical Study in Gout and Hyperuricemia

Fineline Cube Dec 23, 2022

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has announced receiving approval from the National Medical Products...

Company Deals

Innovent Biologics Announces Strategic Partnerships to Form Tumor Diagnosis and Treatment Alliance

Fineline Cube Dec 23, 2022

China-based Innovent Biologics (HKG: 1801) has announced a series of strategic partnerships with compatriot firms...

Company Drug

BioNTech Ships First COVID-19 Vaccine Batches to China

Fineline Cube Dec 22, 2022

BioNTech is reportedly in the process of shipping the first batches of its COVID-19 vaccines...

Company Drug

Merck Launches Noxafil in China for Antifungal Treatment

Fineline Cube Dec 22, 2022

US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) has announced the official market launch...

Company Drug

Hinova’s PROTAC Drug HP518 Accepted for FDA Review in mCRPC

Fineline Cube Dec 22, 2022

China-based biopharma Hinova Pharmaceuticals has announced that a clinical trial filing for its androgen receptor...

Company Drug

Fosun Kite’s CAR-T Therapy FKC889 Approved for Clinical Trials in China

Fineline Cube Dec 22, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its...

Policy / Regulatory

Shanghai Outlines Plans to Boost Healthcare and Pharma Industry

Fineline Cube Dec 22, 2022

Liu Wei, director of the market orders and trade division of the Shanghai Commerce Commission,...

Company Drug

Yantai Dongcheng Receives NMPA Approval for F18 PET Imaging Study

Fineline Cube Dec 22, 2022

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the...

Company Deals

Biomica Raises Funds for Tumor Immunity and IBD Drug Development

Fineline Cube Dec 22, 2022

Israel-based start-up Biomica has reportedly raised an undisclosed amount of money via another financing round,...

Posts pagination

1 … 589 590 591 … 672

Recent updates

  • Peak Pharmaceutical Partners with Shanghai Pharma Subsidiary to Optimize Neffy Supply Chain and Channel Development in China
  • Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis
  • NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking
  • Changchun High & New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease
  • CanSino Biologics Initiates Phase I/II Trial for PCV24 Pneumococcal Conjugate Vaccine with Enhanced Serotype Coverage
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Peak Pharmaceutical Partners with Shanghai Pharma Subsidiary to Optimize Neffy Supply Chain and Channel Development in China

Others

Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis

Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Company Drug

Changchun High & New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.